Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis over 52 weeks: a phase III, randomized, controlled trial (ESTEEM 2)
Promoting cell regeneration: This active ingredient encourages the production of new cells, improving the texture and luminosity of the skin
Engineering bacteria-activated multifunctionalized hydrogel for promoting diabetic wound healing
6 Obesity drugs are expanding beyond BMI reduction The therapeutic scope is moving toward comorbidity modification: type 2 diabetes prevention, glycaemic control, cardiovascular risk reduction, heart failure with preserved ejection fraction, obstructive sleep apnoea, chronic kidney disease and MASH/metabolic liver disease
Bull Exp Biol Med 2002;133:6146